The Pharma Data

JUNE 18, 2025

The investigational ADC is built using Daiichi Sankyo’s proprietary DXd technology and represents one of the newest generation of targeted cancer therapies. It will enroll patients with mCRPC who have experienced disease progression during or after ARPI therapy.

Trials

SugarCone Biotech

JUNE 19, 2025

They have interesting patterns of expression in different cancer indications; thus, diverse therapies for attacking these targets have been developed. SCLC generally has a “hot” tumor microenvironment (TME) meaning that it is infiltrated by immune cells, including the T cells that are activated by immune checkpoint therapies.

Therapies

SugarCone Biotech

JUNE 27, 2025

They have interesting patterns of expression in different cancer indications; thus, diverse therapies for attacking these targets have been developed. As we’ll see, ASCO 2025 was a breakout conference for B7-H3-targeted therapies. Advanced therapies targeting B7-H3 use different modalities, currently dominated by ADCs.

Therapies

Drug Patent Watch

DECEMBER 9, 2024

This includes: Preclinical studies Clinical trials Regulatory approval Manufacturing and marketing Throughout this process, pharmaceutical companies seek to protect their investments through patents.

Drugs

The Pharma Data

JUNE 24, 2025

Oncology remains a core priority, reflecting the rising global burden of cancer and the need for more effective, targeted therapies. The goal is to transform laboratory discoveries into clinically relevant therapies that can reach patients faster and more efficiently.

Pharma R&D

Drug Target Review

JUNE 2, 2025

Bioconjugates are rapidly emerging as a key frontier in targeted therapies, particularly through Antibody-Drug Conjugates (ADCs) , which combine antibodies with cytotoxic drugs to deliver more precise and effective treatments.

Small Molecule

Alta Sciences

JULY 3, 2025

It was the perfect venue for meaningful conversations with pharmaceutical companies, fellow CROs, and academic experts, all eager to explore the latest breakthroughs in drug development. BIG IDEAS AND BRIGHT CONVERSATIONS ABOUT DRUG DEVELOPMENT The CPHI Innovation Theater was buzzing with energy—and Altasciences was right in the mix.

Small Molecule

Drug Target Review

MARCH 3, 2025

In this interview, Professor Schwamborn discusses his research, the promise of brain organoids, and his vision for the future of stem cell-based therapies. However, promising pilot data from ongoing collaborations with pharmaceutical companies suggest that brain organoids are set to become a valuable tool in preclinical research.

Disease

DrugBank

JUNE 18, 2025

Before a therapy can be approved for patient use, it must undergo extensive clinical testing and strictly adhere to regulatory guidelines. This means pharmaceutical companies must remain vigilant and adaptable to comply with evolving regulations. Drug development is a complex and highly regulated process.

Drug Development

Codon

NOVEMBER 3, 2024

The experience showed me that new therapies are needed not only to meet the targets laid out by the End TB Strategy but also to prevent drug resistance from negating the effectiveness of current therapeutics. The drug didn’t cure the animals at such low doses, but their health did improve, hinting at the drug’s efficacy.

Vaccine

Drug Patent Watch

DECEMBER 17, 2024

Contract Development and Manufacturing Organizations (CDMOs) are at the forefront of this shift, playing a crucial role in bringing innovative therapies to market. Let’s dive into the world of pharmaceutical outsourcing and explore why adaptability is the key to success.

Pharmaceuticals

The Pharma Data

JULY 3, 2025

NASDAQ: SBFM), a pharmaceutical company focused on developing and commercializing life-saving medicines across oncology, antiviral therapies, and other therapeutic areas, has announced the commercial launch of its first biosimilar drug, NIOPEG® , in Canada.

Marketing

BioPharma Drive: Drug Pricing

JUNE 11, 2025

Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. Among those who had gotten another such therapy, the rates were 52% and 62% in those trials.

FDA

SugarCone Biotech

JULY 6, 2025

They have interesting patterns of expression in different cancer indications; thus, diverse therapies for attacking these targets have been developed. These results are notable given the poor response of NRG1 fusion driven cancers to chemo- and immuno-therapies. The result is a complex clinical, commercial and competitive landscape.

Drug Development

The Pharma Data

JUNE 20, 2025

The new recommendation supports the use of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC) in the European Union (EU). The Urgent Need for New Prostate Cancer Therapies The need for innovative therapies in prostate cancer remains critical.

Trials

Drug Target Review

MAY 26, 2025

In his role, he provides both strategic and technical guidance to Solvias, a global Contract Research Organisation (CRO) that offers critical analytical services to the pharmaceutical industry. We are driving rapid analytics to support the release of cell and gene therapies and other biologics.

Drug Development

BioPharma Drive: Drug Pricing

JULY 16, 2025

Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime. The Food and Drug Administration’s clearance was controversial.

Therapies

BioPharma Drive: Drug Pricing

JULY 10, 2025

Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. The company noted the review of its quarterly performance is ongoing and that estimates could change once it’s complete.

Drugs

BioPharma Drive: Drug Pricing

JUNE 24, 2025

Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime. By Jonathan Gardner • Sept.

RNA

BioPharma Drive: Drug Pricing

JULY 9, 2025

Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. In 2023, the New Jersey-based company scooped up Prometheus Biosciences for $10.8 You can unsubscribe at anytime.

Clinical Trials

BioPharma Drive: Drug Pricing

JULY 14, 2025

Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. The company has 30 sites across Australia, Canada, North America, the U.K. You can unsubscribe at anytime.

Production

The Pharma Data

JUNE 6, 2025

The Strategic Role of CSOs in a Changing Pharmaceutical Landscape Pharmaceutical contract sales outsourcing is no longer viewed as a temporary or stop-gap measure. Equally important is regulatory compliance. Today’s CSOs are expected to adhere to frameworks like HIPAA , GDPR , the Sunshine Act , and regional promotional codes.

Pharmaceutical Companies

Codon

JULY 14, 2025

NSAIDs may likewise play some as yet undetermined role in neurodegenerative diseases, diabetes, and cancer disease therapy. However, in 1928, the pharmaceutical company manufacturing digoxin invented “ Mother Hutton ” as part of a marketing campaign.

Treatment

The Pharma Data

JUNE 24, 2025

While effective treatments do exist—many of them involving advanced biologic therapies that can slow, halt, or even reverse the progression of these conditions—the cost of care can remain a formidable barrier for many patients, particularly those on fixed or limited incomes. Food and Drug Administration (FDA).

Treatment

The Pharma Data

AUGUST 1, 2025

In 2015, it became the first publicly traded biotech or pharmaceutical company to adopt Public Benefit Corporation (PBC) status. According to the company’s charter, its core public benefit purpose is twofold: The development of novel pharmaceutical therapies for patients with unmet medical needs.

Government

Drug Target Review

FEBRUARY 1, 2024

Historically, what has limited investor interest in funding neurological and psychiatric therapies in development? Investors have historically taken a ‘guilty until proven innocent’ approach to investing in neuroscience therapies. We were able to license a molecule from a multi-national pharmaceutical company.

Therapies

Drug Target Review

JUNE 19, 2024

The mission of Lineage Cell Therapeutics is to deliver on some of the early promises of cell therapy. Cell therapy as a concept is a wonderful idea, but many of the early efforts never generated the kind of clinical data that gets people excited and leads to new medicines. In some cases, cell therapy can be curative for the patient.

Therapies

Drug Channels

MARCH 22, 2024

Adam discusses how patients seeking to access specialty therapies can benefit from a digital intake approach. He then explains three ways that specialty pharmaceutical companies can use digital intake strategies to speed patient enrollment. Today’s guest post comes from Adam Stotts, SVP of Customer Success at AssistRx.

Pharmaceutical Companies

Drug Target Review

AUGUST 6, 2024

Liver Fibrosis : Targeted therapies using ADCs could help reduce liver fibrosis and prevent the progression to cirrhosis. How do companies prioritise their R&D investment between oncology and other therapeutic areas for ADCs? How do companies prioritise their R&D investment between oncology and other therapeutic areas for ADCs?

Therapies

DrugBank

MARCH 7, 2024

Inspired by its success, pharmaceutical companies are pursuing the development of drugs with similar therapeutic profiles, aiming to expand treatment options. Key Players and Challenges For pharmaceutical giants like Novo Nordisk and Eli Lilly, 2024 presents both opportunities and challenges.

Pharmaceutical Companies

DrugBank

OCTOBER 4, 2024

Emerging Markets Emerging markets, particularly in Asia and Latin America, have become increasingly attractive destinations for pharmaceutical M&A activity. The growing middle class and government initiatives to improve access to medicines have created an ecosystem for pharmaceutical companies seeking growth opportunities.

Pharmaceuticals

DrugBank

OCTOBER 17, 2024

By harnessing the vast amounts of data generated throughout the development pipeline, pharmaceutical companies can accelerate the discovery of novel therapies, optimize clinical trial design, enhance drug safety monitoring, and deliver personalized medicine, ultimately improving patient outcomes and transforming the future of healthcare.

Drug Development

Drug Target Review

JANUARY 8, 2024

Contrary to popular belief, ageing is not caused by just random wear and tear of our bodies over time but is instead caused by a discrete set of biological mechanisms that we now better understand and can target with therapies. a commercial stage pharmaceutical company. acquired by Teva Pharmaceuticals in 2014.

Science

DrugBank

MARCH 15, 2024

Eli Lilly's Triumph: Pioneering Solutions in Weight Management Eli Lilly's remarkable achievement with its drug Mounjaro (tirzepatide) in the fourth quarter of 2023 has sent ripples of excitement through the pharmaceutical industry. This has caused a great deal of hesitation from pharmaceutical companies in the past.

Pharmaceutical Companies

The Pharma Data

MAY 27, 2022

Novartis today announced the US Food and Drug Administration (FDA) has granted accelerated approval for Kymriah ® (tisagenlecleucel) for the treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy.

FDA Approval

The Pharma Data

MARCH 29, 2022

Boehringer Ingelheim and Veeva Systems (NYSE: VEEV) today announce Boehringer Ingelheim’s selection of Veeva Development Cloud to drive end-to-end processes and seamless information sharing enterprise wide for greater speed in the delivery of innovative therapies. About Boehringer Ingelheim.

Therapies

PPD

MARCH 26, 2024

The PPD clinical research business of Thermo Fisher Scientific conducts an annual survey of more than 150 leaders at pharmaceutical companies around the globe to assess trends in drug discovery and development, including preferences around outsourcing and functional service provider (FSP) utilization.

Clinical Research